DETAILED ACTION
Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
Status of the Claims
Claims 16 – 31 are pending.
Claims 16 – 18 and 20 – 31 are rejected.
Claim 19 is objected.
Priority
PNG
media_image1.png
126
388
media_image1.png
Greyscale
Receipt is acknowledged of certified copies of papers required by 37 CFR 1.55.
Information Disclosure Statement
The information disclosure statement (IDS) submitted on August 21, 2024 is in compliance with the provisions of 37 CFR 1.97. Accordingly, the information disclosure statement is being considered by the examiner.
Claim Objections
Claim 19 is objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims.
Claim Rejections - 35 USC § 102
The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:
A person shall be entitled to a patent unless –
(a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention.
(a)(2) the claimed invention was described in a patent issued under section 151, or in an application for patent published or deemed published under section 122(b), in which the patent or application, as the case may be, names another inventor and was effectively filed before the effective filing date of the claimed invention.
Claims 16 and 30 – 31 are rejected under 35 U.S.C. 102(a)(1)/102(a)(2) as being anticipated by Furumoto et al. US2013/0143877 A1.
Furumoto et al. teach compound F6-20 (Alectinib) of Production Example 30:
PNG
media_image2.png
232
472
media_image2.png
Greyscale
. See, e.g., paragraph [0678].
Furumoto further teaches mesylate salt (methane sulfonate salt) of compound F6-20 is prepared by dissolving compound F6-20 in dimethyl acetamide at 90 °C, adding aqueous solution of mesylic acid, filtering and drying the precipitated crystals, and pulverizing the monomesylate salt using a jet mill (solid form in claim 31). See, e.g., paragraph [0686].
Therefore, the prior art anticipates the instant claims.
Claim Rejections - 35 USC § 103
The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action:
A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made.
The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows:
1. Determining the scope and contents of the prior art.
2. Ascertaining the differences between the prior art and the claims at issue.
3. Resolving the level of ordinary skill in the pertinent art.
4. Considering objective evidence present in the application indicating obviousness or nonobviousness.
Claims 16 – 18 and 20 – 31 are rejected under 35 U.S.C. 103 as being unpatentable over Furumoto et al. US2013/0143877 A1 in view of Berge et al., Journal of Pharmaceutical Sciences (1977), 66(1), pp. 1-19 (pub. January 1, 1977).
Determining the scope and contents of the prior art
Furumoto et al. teach compound F6-20 (Alectinib) of Production Example 30:
PNG
media_image2.png
232
472
media_image2.png
Greyscale
. See, e.g., paragraph [0678].
Furumoto et al. does not teach the acetate, tartaric acid, maleic acid, fumaric acid (1:1), fumaric acid (1:2) and ethane sulfonate (esylate) salts of compound F6-20.
Berge et al. teach that “[t]he chemical, biological, physical, and economic characteristics of medicinal agents can be manipulated and, hence, often optimized by conversion to a salt form”. See, e.g., pg. 1, 1st paragraph. Berge et al. teach that acetate, tartaric acid, maleic acid, fumaric acid (1:1), fumaric acid (1:2) and ethane sulfonate (esylate) salts are common FDA-approved commercially marketed salts known to be useful for formulation of salts of drugs. See, e.g., pg. 2, Table I.
PNG
media_image3.png
69
352
media_image3.png
Greyscale
PNG
media_image4.png
18
323
media_image4.png
Greyscale
PNG
media_image5.png
19
332
media_image5.png
Greyscale
PNG
media_image6.png
36
353
media_image6.png
Greyscale
Berge also teaches that combining a known drug with one of the anions or cations to prepare the salt does not affect the basic therapeutic properties of the drug, but is used to “prolong the release of the active component, thereby eliminating various undesirable drug properties”. See, e.g., pg. 1, 4th paragraph.
Ascertaining the differences between the prior art and the claims at issue
Compared to claims 16 – 18 and 20 – 31, Furumoto et al. does not specifically teach the acetate, tartaric acid, maleic acid, fumaric acid (1:1), fumaric acid (1:2) and ethane sulfonate (esylate) salts of compound F6-20.
Rationale for a prima face case of obviousness
According to MPEP §2141(III), one of the rationales in the KSR decision states “(C) Use of known technique to improve similar devices (methods, or products) in the same way”. KSR, 550 U.S. at 418, 82 USPQ2d at 1396. Furumoto teaches mesylate salt (methane sulfonate salt) of compound F6-20 is prepared by dissolving compound F6-20 in dimethyl acetamide at 90 °C, adding aqueous solution of mesylic acid, filtering and drying the precipitated crystals, and pulverizing the monomesylate salt using a jet mill (solid form). See, e.g., paragraph [0686]. Berge et al. teach that acetate, tartaric acid, maleic acid, fumaric acid (1:1), fumaric acid (1:2) and ethane sulfonate (esylate) salts are few of the most common FDA-approved commercially marketed salts known to be useful for formulation of salts of drugs. See, e.g., pg. 2, Table I.
PNG
media_image3.png
69
352
media_image3.png
Greyscale
PNG
media_image4.png
18
323
media_image4.png
Greyscale
PNG
media_image5.png
19
332
media_image5.png
Greyscale
PNG
media_image6.png
36
353
media_image6.png
Greyscale
Berge et al. also teaches that preparing an anion salt of the known drug does not affect the therapeutic properties of the drug, but rather prolongs the release of the drug and eliminates various undesirable drug properties. Thus, using the teachings of Berge to obtain the solid forms of acetate, tartaric acid, maleic acid, fumaric acid (1:1), fumaric acid (1:2) and ethane sulfonate (esylate) salts of compound F6-20 would be the same as using a known technique in the art for preparing pharmaceutically acceptable salts to improve similar compounds in the same way. Therefore, the PHOSITA would have been motivated to prepare the solid forms of said salts of acetate, tartaric acid, maleic acid, fumaric acid (1:1), fumaric acid (1:2) and ethane sulfonate (esylate) salts in a similar method of preparing the mesylate salt of compound F6-20 as taught by Furumoto et al. in order to improve the pharmaceutical properties of alectinib.
Therefore, the prior art render the instant claims prima facie obvious.
Conclusion
Any inquiry concerning this communication or earlier communications from the examiner should be directed to Sagar Patel whose telephone number is (571)272-1317. The examiner can normally be reached Monday - Friday: 9am to 5pm EST.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Amy L. Clark can be reached at (571) 272-1310. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/Sagar Patel/Examiner, Art Unit 1626
/KAMAL A SAEED/Primary Examiner, Art Unit 1626